DeepMed Research

CAP256J3LS

Generic Name: CAP256J3LS

Clinical Trials

Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults

Phase 1

Recruiting

Conditions: HIV Infection

Interventions: Biological: VRC-HIVMAB0121-00-AB

First Posted Date: 2024-09-19

Last Posted Date: 2025-03-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT06585891

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy